458 related articles for article (PubMed ID: 15272313)
1. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
2. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
3. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism.
Brader KR; Wolf JK; Hung MC; Yu D; Crispens MA; van Golen KL; Price JE
Clin Cancer Res; 1997 Nov; 3(11):2017-24. PubMed ID: 9815592
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
10. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.
Li J; Dong X; Xu Z; Jiang X; Jiang H; Krissansen GW; Sun X
J Biomed Sci; 2008 Jan; 15(1):99-109. PubMed ID: 17705027
[TBL] [Abstract][Full Text] [Related]
11. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
[TBL] [Abstract][Full Text] [Related]
12. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
14. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
17. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
18. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
Shao R; Lee DF; Wen Y; Ding Y; Xia W; Ping B; Yagita H; Spohn B; Hung MC
Mol Cancer Res; 2005 Apr; 3(4):219-26. PubMed ID: 15831675
[TBL] [Abstract][Full Text] [Related]
19. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo.
Cook JL; Miura TA; Iklé DN; Lewis AM; Routes JM
Cancer Res; 2003 Jun; 63(12):3435-43. PubMed ID: 12810682
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo.
Deng J; Xia W; Hung MC
Oncogene; 1998 Oct; 17(17):2167-75. PubMed ID: 9811448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
